Collegium Pharmaceutical: Stock Deserves A "Buy" Call On Undervaluation Of ADHD Drug

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Collegium Pharmaceuticals (NASDAQ: COLL ) stock trades at >$30 per share, and its market cap is just shy of $1bn (at the time of writing). According to its Q1 2025 quarterly report / 10Q submission :The group is fo ...